POTENTIAL APPROACHES FOR REDUCING AMYLOID β PRODUCTION.
Alzheimer's disease (AD), a neurodegenerative disorder, is associated with the mitochondrial dysfunction, defective synapses, and impaired cognition in elderly patients. The accumulation of amyloid β (Aβ) in synapses and synaptic mitochondria is thought one of the critical pathological events of synaptic defect and impaired mitochondrial dynamics in AD neurons. In order to understand disease progression and designing therapeutic agents using available molecular targets, extensive research is in progress throughout the world. However, no drug has been reported, up to now, as effectively preventing and treating moiety for AD, due to hidden knowledge about exact mode of AD pathogenesis. However, some hypotheses based-drugs, possessing capability of regulating amyloid β precursor protein, have been indicated for alleviation of psychological and behavioral symptoms of AD patients. This review article briefly describes the recent developments made for exploring the Aβ induced-mitochondrial defects in AD and some treatment possibilities through Aβ-targeting approaches for AD therapy.